Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

Phase 2

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: DS107
Drug: Placebo

Registration Number: NCT03817190

Lead Sponsor: DS Biopharma

Brief Summary: The objective of this study is to compare the efficacy and safety of orally administered DS107 (2g) versus placebo in the treatment of moderate to severe Atopic Dermatitis (AD).

Oral DS107/Placebo capsules will be administered for 16 weeks. The study will enrol approximately 220 subjects.

Detailed Description: This study involves a comparison of 2g DS107 with placebo, administered orally once daily for a total of 16 weeks. Patients will be randomized to one of the two treatment arms in a 1:1 ratio.

The primary endpoint will be the vIGA (Validated Investigator's Global Assessment) and EASI (Eczema Area and Severity Index). Other endpoints include vIGA, EASI, SCORAD, BSA (Body Surface Area) and NRS (Numeric Rating Scale).

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 219

Inclusion Criteria

Patients with a clinically confirmed diagnosis of active AD according to the American Academy of Dermatology Consensus Criteria that had been present for at least 6 months before the screening visit.
Patients with moderate to severe AD at baseline as defined by a Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-ADTM) score of 3 Or 4 at baseline.
Patients with an Eczema Area and Severity Index (EASI) score of ≥16 at screening and baseline.
Patients with AD covering a minimum 10% of the Body Surface Area (BSA) at baseline.
Patients with a worst itch Numeric Rating Scale (NRS) score in a day of ≥4 (on 11-point NRS) at the screening and baseline visits.
Patients whose pre-study clinical laboratory findings did not interfere with their participation in the study, in the opinion of the investigator.
Patients who were able and willing to stop all current treatments for AD throughout the study (except for allowed emollients).
Patients who were on a stable dose of a bland emollient for at least 7 days prior to baseline.
Male or female patients aged 18 years and older on the day of signing the informed consent form (ICF).
Female patients and male patients with female partners of child bearing potential had to use highly effective birth control methods or have a sterilised partner for the duration of the study.
Recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications or for whom topical treatments were otherwise medically inadvisable (e.g. because of important side effects or safety risks).
Patients who were able to communicate well with the investigator, to understand and comply with the requirements of the study, and understand and sign the written informed consent prior to initiation of any study specific activities or procedures.

Exclusion Criteria

Patients with other skin conditions that might interfere with AD diagnosis and/or evaluation (such as psoriasis or current active viral, bacterial and fungal topical skin infections) as assessed by the investigator.
Patients who had used systemic treatments that could affect AD less than 4 weeks prior to Baseline Visit (Day 0), e.g. retinoids, methotrexate, cyclosporine, hydroxycarbamide (hydroxyurea), azathioprine and oral/injectable corticosteroids.

Intranasal corticosteroids and inhaled corticosteroids for stable medical conditions were allowed.
Patients with previous exposure to DS107.
Patients who had used any topical medicated treatment for AD (except for emollients) two weeks prior to start of treatment/Baseline (Day 0) including but not limited to, topical corticosteroids, calcineurin inhibitors, tars, bleach, antimicrobials and bleach baths.
Patients who used emollients containing urea, ceramides or hyaluronic acid less than 12 weeks prior to Baseline (Day 0).
Patients who have had excessive sun exposure, have used tanning booths or other ultraviolet (UV) light sources four weeks prior to Baseline (Day 0) and/or were planning a trip to a sunny climate or to use tanning booths or other UV sources between screening and follow-up visits.
Patients who had a history of hypersensitivity to any substance in DS107 or placebo capsules.
Patients who had a history of hypersensitivity to soy beans or soy lecithin.
Patients who had a white cell count or differential white cell count outside of the normal reference range at screening.
Patients who had any clinically significant controlled or uncontrolled medical condition or laboratory abnormality that would, in the opinion of the investigator, put the patient at undue risk or interfere with interpretation of study results.
Patients who had a clinically significant impairment of renal or hepatic function.
Patients with significant uncontrolled cardiovascular, neurologic, malignant, psychiatric, respiratory or hypertensive disease, as well as uncontrolled diabetes and fluoride arthritis or any other illness that, in the opinion of the investigator, was likely to interfere with completion of the study.
Patients with active infectious diseases (e.g. hepatitis B, hepatitis C or advanced disease secondary to infection with human immunodeficiency virus).
Patients with a history of clinically significant drug or alcohol abuse in the opinion of the investigator in the last year prior to Baseline (Day 0).
Patients who had participated in any other clinical study with an investigational drug within 3 months before the first day of administration of study treatment.
Patients who have had treatment with biologics as follows:

Any cell-depleting agents including but not limited to rituximab: within 6 months before the screening visit, or until lymphocyte count returned to normal, whichever was longer. b. Other biologics influencing cell proliferation: within 6 months before the screening visit. c. Dupilumab or other monoclonal antibodies within 5 half-lives (if known) or 16 weeks prior to baseline visit, whichever was longer.
Patients who were pregnant, planning pregnancy, breastfeeding and/or were unwilling to use adequate contraception (as specified in Inclusion Criterion 10) during the trial.
Patients, in the opinion of the investigator, not suitable to participate in the study.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2g Oral DS107	DS107	2g DS107 (4 DS107 capsules) administered once-daily for 16 weeks
Placebo	Placebo	Placebo (4 placebo capsules) orally administered once-daily for 16 weeks

Primary Outcome Measures

Name	Time	Method
Proportion of Patients Achieving EASI-75 in Treated Population Compared to Placebo Population at Week 16.	16 Weeks	Proportion of patients achieving EASI-75 (≥75% improvement from Baseline) in treated population compared to placebo population at Week 16 using GLMM.
Proportion of Patients Achieving a Validated Investigator Global Assessment Scale for Atopic Dermatitis Score of 0 or 1 and a Decrease of at Least 2 Points in vIGA-ADTM in Treated Population Compared to Placebo Population From Baseline at Week 16.	16 Weeks	Proportion of patients achieving a Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-ADTM) score of 0 (clear) or 1 (almost clear) and a decrease of at least 2 points in vIGA-ADTM in treated population compared to placebo population from Baseline at Week 16 using GLMM.The vIGA-ADTM scale awards a score of 0-4 based on a 5-point severity scale from clear to severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease). The scale uses clinical characteristics of erythema, infiltration, papulation and oozing/crusting as scoring guidelines for the overall severity assessment.

Secondary Outcome Measures

Name	Time	Method
Proportion of Patients Achieving a vIGA-ADTM Score of 0 or 1 and a Decrease of at Least 2 Points in vIGA-ADTM in Treated Population Compared to Placebo Population From Baseline to Week 4, 8, 12, 18 and 20.	Baseline, Week 4, Week 8, Week 12, Week 18 and Week 20.	Proportion of patients achieving a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) score of 0 (clear) or 1 (almost clear) and a decrease of at least 2 points in vIGA-ADTM in treated population compared to placebo population from baseline to Week 4, 8, 12, 18 and 20 and the change in proportion of patients from Week 16 to Week 18 and 20. The vIGA-ADTM scale awards a score of 0-4 based on a 5-point severity scale from clear to severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease). The scale uses clinical characteristics of erythema, infiltration, papulation and oozing/crusting as scoring guidelines for the overall severity assessment.
Proportion of Patients Achieving EASI-75 (≥75% Improvement From Baseline) in Treated Population Compared to Placebo Population at Weeks 4, 8, 12, 18 and 20	Baseline, Week 4, Week 8, Week 12, Week 18 and Week 20.	Proportion of Patients Achieving EASI-75 (≥75% Improvement in Eczema Area and Severity Index from Baseline) in Treated Population Compared to Placebo Population at Weeks 4, 8, 12, 18 and 20 EASI quantifies the severity of a patient's AD based on both lesion severity and the percent of BSA affected. The EASI is a composite score ranging from 0-72 that takes into account the degree of erythema, induration/papulation, excoriation, and lichenification (each scored from 0 to 3 separately, half points are permitted) for each of four body regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body.
Change From Baseline in Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-ADTM) Score in Treated Population Compared to Placebo Population to Weeks 4, 8, 12, 16, 18 and 20.	20 Weeks	The Validated Global Investigator Assessment scale for Atopic Dermatitis (vIGA-AD) scale awards a score of 0-4 based on a 5-point severity scale from clear to severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease). The scale uses clinical characteristics of erythema, infiltration, papulation and oozing/crusting as scoring guidelines for the overall severity assessment. A decrease in Validated Global Investigator Assessment scale indicates a positive outcome for the participant.
Change From Baseline in EASI in Treated Population Compared to Placebo Population to Weeks 4, 8, 12, 16, 18 and 20.	Week 20	Change from Baseline in Eczema Area and Severity Index (EASI) in treated population compared to placebo population to Weeks 4, 8, 12, 16, 18 and 20. EASI quantifies the severity of a patient's atopic dermatitis (AD) based on both lesion severity and the percent of body surface area (BSA) affected. The EASI is a composite score ranging from 0 (no lesion severity) to 72 (severe lesions) that takes into account the degree of erythema, induration/papulation, excoriation, and lichenification (each scored from 0 to 3 separately, half points are permitted) for each of four body regions, with adjustment for the percent of Body Surface Area (BSA) involved for each body region and for the proportion of the body region to the whole body. The severity of each sign is assessed using a 4-point scale (half points are permitted): * 0 = none * 1 = mild * 2 = moderate * 3 = severe A decrease in EASI indicates a positive outcome for the participant.
Change From Baseline in Worst Itch NRS in Treated Population Compared to Placebo Population to Week 4, 8, 12, 16, 18.	Week 18	Change from Baseline in worst itch Numeric Rating Scale (NRS) in treated population compared to placebo population to Week 4, 8, 12, 16 and 18. Severity of pruritus related to atopic dermatitis (AD) was self-assessed by patients daily using the NRS. Patients were asked to estimate the intensity of pruritus at its worst over the previous 24 hours. The Pruritus NRS is a single-question assessment tool that was used to assess the patient's worst itch as a result of AD in the previous 24 hours. Patients will score their pruritus due to AD on a scale of 0 - 10, with 0 indicating no itch and 10 indicating the worst itch imaginable. Patients will complete the rating scale daily starting at screening through to the last study visit. A decrease in worst itch NRS indicates a positive outcome for the participant.
Proportion of Patients Achieving a Decrease of at Least 3 Points in Worst Itch NRS in Treated Population Compared to Placebo Population From Baseline to Week 4, 8, 12, 16, 18 and 20.	Week 20	Proportion of Patients Achieving a Decrease of at Least 3 Points in Worst Itch Numeric Rating Scale (NRS) in Treated Population Compared to Placebo Population From Baseline to Week 4, 8, 12, 16, 18 and 20. The Pruritus NRS is a single-question assessment tool that will be used to assess the patient's worst itch as a result of AD in the previous 24 hours. Patients score their pruritus due to AD on a scale of 0 - 10, with 0 (no itch) and 10 (worst itch imaginable). Patients will complete the rating scale daily starting at screening through to the last study visit.
Proportion of Patients Achieving a Decrease of at Least 4 Points in Worst Itch NRS in Treated Population Compared to Placebo Population From Baseline to Week 4, 8, 12, 16, 18 and 20,	Week 20	Proportion of patients achieving a decrease of at least 4 points in worst itch Numeric Rating Scale (NRS) in treated population compared to placebo population from baseline to Week 4, 8, 12, 16, 18 and 20. Severity of pruritus related to atopic dermatitis (AD) was self-assessed by patients daily using the NRS. Patients were asked to estimate the intensity of pruritus at its worst over the previous 24 hours. The Pruritus NRS is a single-question assessment tool that is used to assess the patient's worst itch as a result of AD in the previous 24 hours. Patients will score their pruritus due to AD on a scale of 0 - 10, with 0 indicating no itch and 10 indicating the worst itch imaginable. Patients completed the rating scale daily starting at screening through to the last study visit. A decrease in worst itch NRS indicates a positive outcome for the participant.
Proportion of Patients Achieving EASI-50 (≥50% Improvement From Baseline) in Treated Population Compared to Placebo Population at Week 4, 8, 12, 16, 18 and 20.	Week 20	Proportion of Patients Achieving EASI-50 (≥50% Improvement in Eczema Area and Severity Index From Baseline) in Treated Population Compared to Placebo Population at Week 4, 8, 12, 16, 18 and 20. The EASI is a composite score ranging from 0-72 that takes into account the degree of erythema, induration/papulation, excoriation, and lichenification (each scored from 0 to 3 separately, half points are permitted) for each of four body regions, with adjustment for the percent of Body Surface Area (BSA) involved for each body region and for the proportion of the body region to the whole body. The severity of each sign is assessed using a 4-point scale (half points are permitted): * 0 = none * 1 = mild * 2 = moderate * 3 = severe A decrease in EASI indicates a positive outcome for the participant.
Change From Baseline in the Body Surface Area Affected by AD in Treated Population Compared to Placebo Population to Weeks 4, 8, 12, 16, 18.	Week 18	Change from Baseline in the Body Surface Area (BSA) affected by AD in treated population compared to placebo population to Weeks 4, 8, 12, 16, 18.
Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score in Treated Population Compared to Placebo Population to Weeks 4, 8, 12, 16, 18.	18 Weeks	The SCORing Atopic Dermatitis (SCORAD) grading system was developed by the European Task Force on Atopic Dermatitis and has been a standard tool to assess atopic dermatitis (AD) severity in clinical studies. Six items (erythema, edema/papulation, oozing/crusts, excoriation, lichenification, and dryness) will be selected to evaluate the AD severity. The intensity of each item is graded using a 4-point scale: * 0 = No symptoms * 1 = Mild * 2 = Moderate * 3 = Severe The overall body surface area (BSA) affected by AD is evaluated (from 0 to 100%) and included in the SCORAD scores. Loss of sleep and pruritus will be evaluated by patients on a visual analog scale (0-10).
Incidence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs).	20 Weeks	Incidence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Safety Analysis Set.

Trial Locations

Locations (50): DS Investigational Site 527
🇺🇸
Doral, Florida, United States
DS Investigational Site 521
🇺🇸
Medford, Oregon, United States
DS Investigational Site 101
🇦🇹
Graz, Austria
DS Investigational Site 303
🇱🇻
Riga, Latvia
DS Investigational Site 407
🇵🇱
Warsaw, Poland
DS Investigational Site 208
🇩🇪
Berlin, Germany
DS Investigational Site 206
🇩🇪
Essen, Germany
DS Investigational Site 519
🇺🇸
Troy, Michigan, United States
DS Investigational Site 517
🇺🇸
Washington, District of Columbia, United States
DS Investigational Site 526
🇺🇸
Grants Pass, Oregon, United States
DS Investigational Site 201
🇩🇪
Frankfurt, Germany
DS Investigational Site 205
🇩🇪
Luebeck, Germany
DS Investigational Site 518
🇺🇸
Kenosha, Wisconsin, United States
DS Investigational Site 207
🇩🇪
Gera, Germany
DS Investigational Site 210
🇩🇪
Mainz, Germany
DS Investigational Site 214
🇩🇪
Münster, Germany
DS Investigational Site 304
🇱🇻
Jūrmala, Latvia
DS Investigational Site 525
🇺🇸
Philadelphia, Pennsylvania, United States
DS Investigational Site 509
🇺🇸
Arlington, Texas, United States
DS Investigational Site 512
🇺🇸
Columbus, Georgia, United States
DS Investigational Site 506
🇺🇸
Austin, Texas, United States
DS Investigational Site 508
🇺🇸
Cypress, Texas, United States
DS Investigational Site 507
🇺🇸
San Antonio, Texas, United States
DS Investigative Site 530
🇺🇸
Salt Lake City, Utah, United States
DS Investigational Site 502
🇺🇸
Los Angeles, California, United States
DS Investigational Site 528
🇺🇸
Huntington Beach, California, United States
DS Investigational Site 513
🇺🇸
Louisville, Kentucky, United States
DS Investigational Site 524
🇺🇸
Birmingham, Alabama, United States
DS Investigational Site 505
🇺🇸
San Diego, California, United States
DS Investigational Site 504
🇺🇸
San Diego, California, United States
DS Investigational Site 501
🇺🇸
Santa Monica, California, United States
DS Investigational Site 516
🇺🇸
Santa Ana, California, United States
DS Investigational Site 514
🇺🇸
Skokie, Illinois, United States
DS Investigational Site 511
🇺🇸
Raleigh, North Carolina, United States
DS Investigational Site 403
🇵🇱
Poznań, Poland
DS Investigative Site 529
🇺🇸
Orem, Utah, United States
DS Investigational Site 202
🇩🇪
Berlin, Germany
DS Investigational Site 203
🇩🇪
Augsburg, Germany
DS Investigational Site 204
🇩🇪
Dresden, Germany
DS Investigational Site 211
🇩🇪
Leipzig, Germany
DS Investigational Site 212
🇩🇪
Rostock, Germany
DS Investigational Site 301
🇱🇻
Riga, Latvia
DS Investigational Site 302
🇱🇻
Riga, Latvia
DS Investigational Site 405
🇵🇱
Warsaw, Poland
DS Investigational Site 305
🇱🇻
Riga, Latvia
DS Investigational Site 406
🇵🇱
Gdańsk, Poland
DS Investigational Site 402
🇵🇱
Łódź, Poland
DS Investigational Site 401
🇵🇱
Wrocław, Poland
DS Investigational Site 523
🇺🇸
Richmond, Virginia, United States
DS Investigational Site 510
🇺🇸
Sunrise, Florida, United States